Berlin - Delayed Quote EUR

Rocket Pharmaceuticals Inc (9IP1.BE)

22.42 -0.13 (-0.58%)
As of 8:30 PM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
259,659.00
259,659.00
223,843.00
166,248.00
134,303.00
Operating Income
-259,659.00
-259,659.00
-223,843.00
-166,248.00
-134,303.00
Net Non Operating Interest Income Expense
14,064.00
14,064.00
1,980.00
-2,821.00
-5,397.00
Other Income Expense
--
--
--
--
-580.00
Pretax Income
-245,595.00
-245,595.00
-221,863.00
-169,069.00
-139,700.00
Net Income Common Stockholders
-245,595.00
-245,595.00
-221,863.00
-169,069.00
-139,700.00
Diluted NI Available to Com Stockholders
-245,595.00
-245,595.00
-221,863.00
-169,069.00
-139,700.00
Basic EPS
-2.92
--
-3.26
-2.67
-2.52
Diluted EPS
-2.92
--
-3.26
-2.67
-2.52
Basic Average Shares
84,009.00
--
68,148.93
63,235.42
55,380.74
Diluted Average Shares
84,009.00
--
68,148.93
63,235.42
55,380.74
Total Operating Income as Reported
-259,659.00
-259,659.00
-224,343.00
-167,248.00
-134,303.00
Total Expenses
259,659.00
259,659.00
223,843.00
166,248.00
134,303.00
Net Income from Continuing & Discontinued Operation
-245,595.00
-245,595.00
-221,863.00
-169,069.00
-139,700.00
Normalized Income
-245,595.00
-245,595.00
-221,863.00
-169,069.00
-139,700.00
Interest Income
15,939.00
15,939.00
3,889.00
3,068.00
2,150.00
Interest Expense
1,875.00
1,875.00
1,909.00
5,889.00
7,547.00
Net Interest Income
14,064.00
14,064.00
1,980.00
-2,821.00
-5,397.00
EBIT
-243,720.00
-243,720.00
-219,954.00
-163,180.00
-132,153.00
EBITDA
-236,622.00
-236,622.00
-213,688.00
-157,807.00
-125,903.00
Reconciled Depreciation
7,098.00
7,098.00
6,266.00
5,373.00
6,250.00
Net Income from Continuing Operation Net Minority Interest
-245,595.00
-245,595.00
-221,863.00
-169,069.00
-139,700.00
Normalized EBITDA
-236,622.00
-236,622.00
-213,688.00
-157,807.00
-125,903.00
12/31/2020 - 12/15/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade